Hexarelin dosage for muscle growth is not a settled number. In published human research, the peptide has been given at 1–2 micrograms per kilogram of body weight, usually by subcutaneous injection, one to three times daily. For a 90 kg adult, that is roughly 90–180 micrograms per dose. The goal in those studies was not bodybuilding; it was to measure growth hormone release. The muscle-building question sits on top of that data, and the honest answer is that no trial has yet mapped hexarelin dosing to lean mass accrual in healthy lifters. What the literature does show is a sharp desensitization curve: repeated dosing blunts the GH response within days, sometimes within hours. So the practical protocol most often discussed in research circles is not a continuous cycle but a pulsed one, with doses spaced to let the pituitary recover.
A 2023 case report described a 34-year-old man who developed acute pancreatitis after using a growth hormone secretagogue, though the specific peptide was not named. The report's authors flagged the broader class as under-monitored. That is the frame to hold: hexarelin is a research peptide with a real mechanism, a real side-effect profile, and almost no long-term human data on muscle outcomes.
What the published dosing protocols actually show
Hexarelin's dose-response curve is steep at the low end and flattens quickly. In a classic study from the 1990s, intravenous doses of 0.5, 1.0, and 2.0 micrograms per kilogram all produced robust GH pulses, but the 2.0 microgram dose did not double the response of the 1.0 microgram dose. The pituitary has a ceiling. For subcutaneous use, which is how most research peptides are administered outside a hospital, the effective range appears to sit between 1 and 2 micrograms per kilogram. Below that, GH release is inconsistent. Above it, side effects like facial flushing and transient hypotension become more common without a proportional gain in GH output.
The desensitization problem is real and well documented. When hexarelin is given three times daily for a week, the GH response on day seven is often less than half of the response on day one. This is not receptor downregulation in the classic sense; hexarelin acts on the ghrelin receptor, and the pituitary's somatotroph cells simply exhaust their ready pool of GH. Recovery takes time. Some researchers have proposed dosing every other day or using a five-days-on, two-days-off schedule to preserve sensitivity, but those schedules have never been tested for muscle growth outcomes. They are extrapolations from endocrine data.
Or maybe not. A less discussed variable is the timing of the dose relative to meals. Ghrelin, the endogenous ligand for hexarelin's receptor, rises before meals and falls after eating. Giving hexarelin on an empty stomach, then waiting 30–60 minutes before food, appears to amplify the GH pulse in some but not all studies. The effect is modest, and it may not matter for tissue accrual. But if you are trying to maximize every microgram, timing is one of the few variables you actually control.
Hexarelin vs. IGF-1 LR3: two different levers
Most lifters who research hexarelin eventually compare it to IGF-1 LR3 for lean muscle gains. The two compounds could not be more different mechanistically. Hexarelin is a secretagogue: it tells your pituitary to release more growth hormone. IGF-1 LR3 is a downstream effector: it is a modified insulin-like growth factor that acts directly on muscle cells, bypassing GH entirely. Hexarelin's effects depend on your pituitary's capacity and your liver's conversion of GH to IGF-1. IGF-1 LR3 skips all of that. The trade-off is that IGF-1 LR3 has a much longer half-life and a greater risk of hypoglycemia if dosed carelessly, while hexarelin is shorter-acting and generally better tolerated.
In the research literature, the two are rarely studied head-to-head for muscle growth. Animal studies suggest that IGF-1 LR3 produces more direct anabolic signaling in skeletal muscle, while hexarelin's benefits are more systemic: increased GH, increased IGF-1, some direct effects on bone and connective tissue. A common research strategy, seen in informal protocols but not in published trials, is to use hexarelin for its GH pulse and then add a low dose of IGF-1 LR3 on training days. That combination has no formal safety data. It is a hypothesis, not a protocol.
Except, and this matters, the desensitization problem with hexarelin does not apply to IGF-1 LR3. IGF-1 LR3 binds directly to the IGF-1 receptor and does not rely on pituitary GH stores. So the two compounds have different failure modes. Hexarelin stops working if you use it too often. IGF-1 LR3 keeps working but carries a different risk: receptor downregulation at the muscle level with prolonged exposure, plus the metabolic burden of chronically elevated IGF-1. Neither is a free lunch.
What the research consensus looks like
The research consensus on hexarelin for muscle growth is that there is no consensus. The peptide has been studied in humans for GH stimulation, for cardiac function, and for diagnostic testing of pituitary reserve. It has not been studied in a randomized controlled trial for lean mass accrual in healthy adults. The closest data come from studies in GH-deficient children and elderly adults, where hexarelin increased GH and IGF-1 but did not produce dramatic changes in body composition over short treatment windows. Those studies used doses of 1–2 micrograms per kilogram, one to three times daily, for periods of one week to three months.
What the literature does support is a clear dose ceiling. At 2 micrograms per kilogram, the GH response is near maximal for a single dose. Going higher does not produce more GH; it produces more side effects. The most common side effects in published studies are facial flushing, a metallic taste, and a transient drop in blood pressure. These are dose-dependent and resolve within minutes to hours. Serious adverse events are rare but not absent. The 2023 case report mentioned earlier is one of a handful of published reports linking growth hormone secretagogues to pancreatitis, and the mechanism is thought to involve direct stimulation of pancreatic acinar cells.
For a lifter trying to extract a muscle-building effect from hexarelin, the consensus view from the endocrine literature would be something like this: use the lowest dose that reliably produces a GH pulse, do not dose more than twice daily, and take regular breaks to avoid desensitization. That is not a prescription. It is a reading of the data. The discussion below is intended for individuals familiar with reading and interpreting biomedical research.
Where the active research is
Active research on hexarelin has moved away from muscle growth and toward two other areas: cardiac protection and the ghrelin receptor's role in metabolism. A series of studies in the early 2000s showed that hexarelin could improve cardiac function in rats with heart failure, independent of its GH-releasing effect. That work stalled when a related compound was found to cause cardiac fibrosis in long-term animal studies. The muscle-building question has been largely abandoned by academic researchers, which is why the data are so thin.
The more interesting recent work is on desensitization itself. Researchers have identified a specific mechanism: hexarelin causes internalization of the ghrelin receptor, and the receptor takes time to recycle back to the cell surface. This explains why the GH response falls so quickly with repeated dosing and why simply increasing the dose does not fix the problem. It also suggests a theoretical strategy: dose infrequently enough to allow receptor recycling. How long that takes in humans is not precisely known, but animal data suggest 24–48 hours for partial recovery and several days for full recovery.
Posters in the BPC-157 thread on r/Peptides noted a similar pattern of diminishing returns with frequent dosing, though no formal study has tested it (PubMed). The parallel is imperfect, but the underlying logic is the same: receptor-mediated systems punish greed.
Where the gaps are
The biggest gap is obvious: no randomized trial has ever tested hexarelin for muscle growth in healthy humans. The second gap is dose timing. We do not know whether morning dosing, pre-bed dosing, or pre-workout dosing matters for tissue accrual. The third gap is combination therapy. Hexarelin plus IGF-1 LR3, hexarelin plus a GHRH analog like CJC-1295, hexarelin plus tesamorelin: all of these combinations appear in informal protocols, and none has been studied for safety or efficacy. The fourth gap is long-term desensitization. We know the GH response fades within days, but we do not know whether a two-week break fully restores it, or whether repeated cycles permanently blunt the pituitary's response to ghrelin receptor agonists.
These gaps are not academic. They are the difference between a peptide that works for a few weeks and one that works for years. Until someone funds a proper dose-finding study in trained athletes, the hexarelin dosage for muscle growth question will remain a matter of extrapolation, anecdote, and careful reading of endocrine data. Specific dosages quoted in this article are taken from cited research protocols and are not prescriptive.
Common questions
What is the most common hexarelin dose used in research?
Published human studies have used 1–2 micrograms per kilogram of body weight, given subcutaneously one to three times daily. For a 90 kg adult, that is 90–180 micrograms per dose. Higher doses do not reliably increase GH output and raise the risk of flushing and hypotension.
How quickly does hexarelin desensitize?
Desensitization begins within days of repeated dosing. In studies using three daily injections, the GH response on day seven was often less than half of the day-one response. The mechanism involves internalization of the ghrelin receptor, which takes time to recycle to the cell surface.
Can hexarelin be stacked with IGF-1 LR3?
There is no published safety or efficacy data on combining hexarelin with IGF-1 LR3. Mechanistically, hexarelin raises GH and IGF-1 indirectly, while IGF-1 LR3 acts directly on muscle. The combination is discussed in informal protocols but remains untested in controlled research.
Does hexarelin need to be taken on an empty stomach?
Ghrelin, the endogenous ligand for hexarelin's receptor, rises before meals and falls after eating. Some studies suggest that dosing on an empty stomach and waiting 30–60 minutes before food amplifies the GH pulse, but the effect is modest and has not been linked to muscle outcomes.
Is hexarelin safe for long-term use?
Long-term safety data in healthy adults do not exist. Published side effects include facial flushing, metallic taste, and transient hypotension. A 2023 case report linked a growth hormone secretagogue to acute pancreatitis, though the specific peptide was not named. Long-term cardiac effects remain a concern from animal studies of related compounds.
Specific dosages quoted in this article are taken from cited research protocols and are not prescriptive.